EGFR and neoplasm: THL delivery of plasmid DNA encoding either antisense RNA [911] or shRNA [1043] directed against the EGFR has a therapeutic effect in brain cancer, but needs to be combined with other therapies that halt tumor progression before the sharp decline in tumor vasculature that occurs in the terminal stages of the tumor growth.